symbol,statement_type,period_end,line_item,value
MONOPHARMA.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.304062
MONOPHARMA.NS,income,2025-03-31 00:00:00,Normalized EBITDA,86171000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Total Unusual Items,0.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,30902000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,1287000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,1523178000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,EBITDA,86171000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,EBIT,84884000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Net Interest Income,-40255000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Interest Expense,40255000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Interest Income,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Normalized Income,30902000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,30902000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Total Expenses,1608354000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Diluted Average Shares,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Basic Average Shares,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Diluted EPS,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Basic EPS,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,30902000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,30902000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Net Income,30902000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Minority Interests,-157000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,31059000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,31059000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Tax Provision,13570000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Pretax Income,44629000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,9788000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Special Income Charges,0.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Write Off,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-40255000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,40255000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Operating Income,75095000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Operating Expense,85176000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Other Operating Expenses,46022000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,1287000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,1287000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Selling General And Administration,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
MONOPHARMA.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
MONOPHARMA.NS,income,2025-03-31 00:00:00,Gross Profit,160271000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Cost Of Revenue,1523178000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Total Revenue,1683449000.0
MONOPHARMA.NS,income,2025-03-31 00:00:00,Operating Revenue,1683449000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.237818
MONOPHARMA.NS,income,2024-03-31 00:00:00,Normalized EBITDA,64241000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Total Unusual Items,0.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,24513000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,1152000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,1106760000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,EBITDA,64241000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,EBIT,63089000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Net Interest Income,-30829000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Interest Expense,30829000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Interest Income,258000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Normalized Income,24513000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,24513000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Total Expenses,1161266000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,1607000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Diluted Average Shares,15514557.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Basic Average Shares,15514557.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Diluted EPS,1.58
MONOPHARMA.NS,income,2024-03-31 00:00:00,Basic EPS,1.58
MONOPHARMA.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,24513000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,24513000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Net Income,24513000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Minority Interests,-75000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,24588000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,24588000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Tax Provision,7672000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Pretax Income,32260000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,954000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Special Income Charges,0.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Write Off,1897000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-30829000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,2363000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,30829000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,258000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Operating Income,62136000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Operating Expense,54506000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Other Operating Expenses,18215000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,1152000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,1152000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Selling General And Administration,6889000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,4305000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,General And Administrative Expense,2584000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,1607000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Gross Profit,116642000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Cost Of Revenue,1106760000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Total Revenue,1223402000.0
MONOPHARMA.NS,income,2024-03-31 00:00:00,Operating Revenue,1223402000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.264034
MONOPHARMA.NS,income,2023-03-31 00:00:00,Normalized EBITDA,31025000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Total Unusual Items,0.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,12320000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,474000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,533379000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,EBITDA,31025000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,EBIT,29988000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Net Interest Income,-13225000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Interest Expense,13225000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Interest Income,26000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Normalized Income,12320000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,12320000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Total Expenses,556144000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,1053000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Diluted Average Shares,17668564.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Basic Average Shares,17668564.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Diluted EPS,0.697284
MONOPHARMA.NS,income,2023-03-31 00:00:00,Basic EPS,0.697284
MONOPHARMA.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,12320000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,12320000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Net Income,12320000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Minority Interests,-17000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,12337000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,12337000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Tax Provision,4426000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Pretax Income,16763000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,1368000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Special Income Charges,0.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Write Off,0.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,-13225000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,1055000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,13225000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,26000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Operating Income,28620000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Operating Expense,22765000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Other Operating Expenses,10688000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,1037000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,1037000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Selling General And Administration,1872000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,8000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,General And Administrative Expense,1864000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,1053000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Gross Profit,51385000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Cost Of Revenue,533379000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Total Revenue,584764000.0
MONOPHARMA.NS,income,2023-03-31 00:00:00,Operating Revenue,584764000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.363042
MONOPHARMA.NS,income,2022-03-31 00:00:00,Normalized EBITDA,13138000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Total Unusual Items,0.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,3509000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,1082000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,346914000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,EBITDA,13138000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,EBIT,12056000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Net Interest Income,-7328000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Interest Expense,6547000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Interest Income,93000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Normalized Income,3509000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,3509000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Total Expenses,358096000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,900000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Diluted Average Shares,17668564.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Basic Average Shares,17668564.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Diluted EPS,0.198601
MONOPHARMA.NS,income,2022-03-31 00:00:00,Basic EPS,0.198601
MONOPHARMA.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,3509000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,3509000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Net Income,3509000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Minority Interests,0.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,3509000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,3509000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Tax Provision,2000000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Pretax Income,5509000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,1104000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Special Income Charges,0.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Write Off,0.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-7328000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,874000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,6547000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,93000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Operating Income,11734000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Operating Expense,11182000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Other Operating Expenses,2613000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,1082000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,1082000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Selling General And Administration,370000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,0.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,General And Administrative Expense,370000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,900000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Gross Profit,22916000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Cost Of Revenue,346914000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Total Revenue,369830000.0
MONOPHARMA.NS,income,2022-03-31 00:00:00,Operating Revenue,369830000.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Total Unusual Items,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
MONOPHARMA.NS,income,2021-03-31 00:00:00,EBITDA,
MONOPHARMA.NS,income,2021-03-31 00:00:00,EBIT,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Net Interest Income,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Interest Expense,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Interest Income,0.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Normalized Income,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Total Expenses,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,570000.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Diluted Average Shares,17668564.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Basic Average Shares,17668564.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Diluted EPS,0.053824
MONOPHARMA.NS,income,2021-03-31 00:00:00,Basic EPS,0.053824
MONOPHARMA.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Net Income,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Minority Interests,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Tax Provision,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Pretax Income,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Special Income Charges,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Write Off,0.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,171000.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,0.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Operating Income,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Operating Expense,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Selling General And Administration,300000.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,64000.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,General And Administrative Expense,236000.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,570000.0
MONOPHARMA.NS,income,2021-03-31 00:00:00,Gross Profit,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Total Revenue,
MONOPHARMA.NS,income,2021-03-31 00:00:00,Operating Revenue,
